Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $654,931 | $422,956 | $476,480 | $683,426 |
| - Cash | $83,005 | $98,434 | $156,152 | $59,774 |
| + Debt | $2,151 | $3,590 | $5,189 | $0 |
| Enterprise Value | $574,077 | $328,112 | $325,517 | $623,652 |
| Revenue | $0 | $0 | $0 | $18,943 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$306 | $0 | $0 | $18,943 |
| % Margin | – | – | – | 100% |
| EBITDA | -$167,152 | -$190,339 | -$132,044 | -$67,901 |
| % Margin | – | – | – | -358.4% |
| Net Income | -$167,383 | -$153,162 | $111,214 | -$65,570 |
| % Margin | – | – | – | -346.1% |
| EPS Diluted | -3.11 | -3.69 | 2.38 | -1.48 |
| % Growth | 15.7% | -255% | 260.8% | – |
| Operating Cash Flow | -$145,303 | -$134,275 | -$126,664 | -$43,433 |
| Capital Expenditures | $0 | -$208 | -$1,133 | -$589 |
| Free Cash Flow | -$145,303 | -$134,483 | -$127,797 | -$44,022 |